Ryan McDonald, Associate Editorial Director for CURE®, has been with the team since February 2020 and has previously covered medical news across several specialties prior to joining MJH Life Sciences. He is a graduate of Temple University, where he studied journalism and minored in political science and history. He considers himself a craft beer snob and would like to open a brewery in the future. During his spare time, he can be found rooting for all major Philadelphia sports teams. Follow Ryan on Twitter @RMcDonald11 or email him at [email protected].
The combination of mirvetuximab soravtansine and Avastin (bevacizumab) demonstrated encouraging overall response rates in patients with ovarian cancer, regardless of the disease’s previous responsiveness to platinum-based chemotherapy, according to data presented at the 2020 ASCO Virtual Scientific Program.
The Food and Drug Administration (FDA) has granted accelerated approval to expand the indication of Gardasil 9 (Human papillomavirus 9-valent vaccine, recombinant), a vaccine for the prevention of HPV, to prevent oropharyngeal and other head and neck cancers caused by certain HPV types.
At a median follow-up of 19.7 months, patients who received the combination achieved an objective response rate (the proportion of patients who had a complete or partial response to treatment) of 27%.
“On the basis of these results, (LuPSMA) appears to represent a new class of effective therapy for men with metastatic castration-resistant prostate cancer,” said Dr. Michael S. Hofman.
The Food and Drug Administration approves Nyvepria, the biosimilar to Neulasta, to help treat and prevent infections in patients undergoing myelosuppressive chemotherapy.
The presentation of the complete data from the NRG-GY004 trial comes just months after AstraZeneca and Merck announced in a press release that the combination failed to meet its primary endpoint of progression-free survival.
“These results provide compelling evidence for early darolutamide (Nubeqa) treatment in men with nonmetastatic CRPC,” lead study author Dr. Karim Fizazi, said in a virtual presentation during the meeting.
After a median follow-up of 15.8 months, patients within the mCRPC cohort who received the combination achieved an objective response rate of 33%.
“These results continue to support pembrolizumab (Keytruda) plus axitinib (Inlyta) as a standard of care for patients with previously untreated advanced RCC,” said lead study author Dr. Elizabeth R. Plimack.
“The superior efficacy of venetoclax-obinutuzumab has been observed and maintained in the current follow up,” Dr. Othman Al-Sawaf, of University Hospital of Cologne in Germany, said during a pre-recording presentation at the 2020 ASCO Virtual Scientific Program.
“Collectively, these results support acalabrutinib (Calquence) use in upfront CLL,” said Dr. John C. Byrd. “This is compounded and supported by two additional phase III studies that have been completed with this agent.”
In this episode of the “CURE Talks Cancer” podcast, we spoke with a gynecologic oncologist and advanced pelvic surgeon who discussed how patients can work to improve their sexual health while facing cancer and its treatments.
CC-92480, a novel cereblon E3 ligase modulator agent, in combination with dexamethasone appeared safe and active in patients with heavily pretreated relapsed or refractory multiple myeloma, according to data presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program.
“Altogether, this pharmacological data supports the concept of CAR T-cell therapy being able to overcome MCL disease with poor risk factors,” said lead study author Dr. Luhua (Michael) Wang.
“The approval of this new firstline metastatic EGFR-mutated non-small cell lung cancer regimen … is an important milestone in the treatment of this disease,” said Dr. Edward Garon.
The Food and Drug Administration approved the combination of Tecentriq and Avastin in patients with unresectable or metastatic hepatocellular carcinoma, making it the first immunotherapy regimen to be approved for this cancer type.
From a five-year-old patient with liver cancer receiving a birthday surprise to a mother-daughter duo releasing a children’s book to help families going through breast cancer treatment, here’s what is making headlines in the cancer space this week.
“The cancer care community urgently needs data on the effects of COVID-19, specifically in patients with cancer,” ASCO President Dr. Howard A. Burris III said in a press release.
“Those who are doing well and are stable in terms of safety and tolerability can come into the office less often,” Dr. David R. Spigel, said. “(This is) a big win.”
In this episode of the “CURE Talks Cancer” podcast, we spoke with a cervical cancer survivor - who is currently living with ovarian cancer - about a cross-country journey she took last summer on a teal and white Harley Davidson motorcycle to raise ovarian cancer awareness.
The Food and Drug Administration recently approved the combination of Lynparza (olaparib) and Avastin (bevacizumab) for patients with advanced ovarian cancer that carries a specific mutation and has responded to previous treatment with platinum-based chemotherapy plus Avastin. Here’s what you need to know.
The Food and Drug Administration’s recent approval of Zejula is different from previous approvals as it is indicated for all patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer, according to a gynecologic oncology expert.
“The intervention described in this abstract is important in that it provides clear and concrete activities — videoconference and coaching — caregivers can participate in to decrease anxiety and stress,” according to one expert.
Obesity was associated with increased cardiovascular disease-related mortality and all-cause mortality, as well as potentially increased prostate cancer-specific mortality, in survivors of nonmetastatic prostate cancer.
The Food and Drug Administration’s recent approval of the first antibody-drug conjugate to treat patients with pretreated metastatic triple-negative breast cancer is a major milestone, according to one expert.
The Food and Drug Administration’s recent approval of Pemazyre (pemigatinib) is a ‘huge milestone’ for patients with cholangiocarcinoma, according to the advocacy coordinator with the Cholangiocarcinoma Foundation.
The Food and Drug Administration approved Darzalex Faspro (daratumumab and hyaluronidase-fihj), a subcutaneous form of Darzalex, for adults with newly diagnosed or relapsed/refractory multiple myeloma.
As patients begin to look at what’s to come when lockdown measures in place are relaxed a new logistical puzzle will pop for some.
Here is a list of the recent trial initiations that occurred within the cancer space in April.
There are advantages and disadvantages to delaying elective reconstructive breast surgery, according to one expert.
